CA2049342A1 - Formules pour stabiliser les anticorps igm - Google Patents

Formules pour stabiliser les anticorps igm

Info

Publication number
CA2049342A1
CA2049342A1 CA 2049342 CA2049342A CA2049342A1 CA 2049342 A1 CA2049342 A1 CA 2049342A1 CA 2049342 CA2049342 CA 2049342 CA 2049342 A CA2049342 A CA 2049342A CA 2049342 A1 CA2049342 A1 CA 2049342A1
Authority
CA
Canada
Prior art keywords
composition
igm
sodium
lyophilized
igm antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA 2049342
Other languages
English (en)
Inventor
Sally Bolmer
Jeffrey A. Mattis
Christopher P. Phillips
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Biotech Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2049342A1 publication Critical patent/CA2049342A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA 2049342 1989-03-27 1990-03-13 Formules pour stabiliser les anticorps igm Abandoned CA2049342A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32857989A 1989-03-27 1989-03-27
US328,579 1989-03-27

Publications (1)

Publication Number Publication Date
CA2049342A1 true CA2049342A1 (fr) 1990-09-28

Family

ID=23281559

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2049342 Abandoned CA2049342A1 (fr) 1989-03-27 1990-03-13 Formules pour stabiliser les anticorps igm

Country Status (4)

Country Link
EP (1) EP0465513A1 (fr)
JP (1) JPH04504253A (fr)
CA (1) CA2049342A1 (fr)
WO (1) WO1990011091A1 (fr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT63343A (en) * 1990-07-03 1993-08-30 Akzo Nv Process for producing immunereactive compounds
JPH0565233A (ja) * 1991-03-08 1993-03-19 Mitsui Toatsu Chem Inc モノクローナル抗体含有凍結乾燥製剤
WO1993006862A1 (fr) * 1991-10-11 1993-04-15 Toray Industries, Inc. Composition a base d'anticorps
EP0621774B1 (fr) * 1992-01-21 1996-12-18 Sri International Procede ameliore de preparation de medicaments polypeptides sous forme de poudre
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6991790B1 (en) 1997-06-13 2006-01-31 Genentech, Inc. Antibody formulation
AU2444899A (en) * 1998-01-22 1999-08-09 Astrazeneca Ab Pharmaceutical formulation comprising an antibody and a citrate buffer
DE60139944D1 (de) 2000-10-12 2009-10-29 Genentech Inc Niederviskose konzentrierte proteinformulierungen
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
DE60229961D1 (de) * 2001-08-29 2009-01-02 Chugai Pharmaceutical Co Ltd Antikörper enthaltende stabilisierte zubereitungen
JP5290489B2 (ja) 2001-11-08 2013-09-18 アッヴィ・バイオセラピューティクス・インコーポレイテッド Ｉｇｇ抗体の安定な液体医薬製剤
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
PT1610820E (pt) 2003-04-04 2010-12-16 Novartis Ag Formulações de elevada concentração de anticorpos e proteínas
JP5322405B2 (ja) * 2007-06-07 2013-10-23 小林製薬株式会社 タンパク質含有組成物
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
BRPI1006519A2 (pt) 2009-03-06 2016-08-09 Genentech Inc formulação de anticorpos
EP2542257B1 (fr) 2010-03-01 2017-07-05 Bayer Healthcare LLC Optimisation d'anticorps monoclonaux dirigés contre l'inhibiteur de la voie du facteur tissulaire (tfpi)
US20110311547A1 (en) 2010-06-18 2011-12-22 Xbiotech, Inc. Arthritis Treatment
KR20130108305A (ko) 2010-08-23 2013-10-02 엑스바이오테크, 인크. 종양성 질병들에 대한 치료
EP2707030B1 (fr) 2011-05-09 2020-02-19 Mayo Foundation For Medical Education And Research Traitements du cancer
BR112014000042A2 (pt) 2011-07-05 2017-02-21 Novozymes Biopharma Dk As composição, meio de cultura celular, uso de uma composição, e, método para cultivar células
US9809649B2 (en) 2011-09-23 2017-11-07 Xbiotech, Inc. Cachexia treatment
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
CA2917407C (fr) 2012-10-01 2023-03-14 Mayo Foundation For Medical Education And Research Complexes de nanoparticules d'anticorps-albumine pour le traitement du cancer
CA2952424C (fr) 2014-06-16 2019-07-23 Mayo Foundation For Medical Education And Research Traitement de myelomes
CN107073132B (zh) * 2014-10-06 2021-08-27 梅约医学教育与研究基金会 载体-抗体组合物及其制备和使用方法
US9446148B2 (en) 2014-10-06 2016-09-20 Mayo Foundation For Medical Education And Research Carrier-antibody compositions and methods of making and using the same
TW201707725A (zh) 2015-08-18 2017-03-01 美國馬友醫藥教育研究基金會 載體－抗體組合物及其製造及使用方法
JP6921802B2 (ja) * 2015-08-18 2021-08-18 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチＭａｙｏ Ｆｏｕｎｄａｔｉｏｎ Ｆｏｒ Ｍｅｄｉｃａｌ Ｅｄｕｃａｔｉｏｎ Ａｎｄ Ｒｅｓｅａｒｃｈ キャリア結合剤組成物およびそれを作製および使用する方法
TW201713360A (en) 2015-10-06 2017-04-16 Mayo Foundation Methods of treating cancer using compositions of antibodies and carrier proteins
WO2017120501A1 (fr) 2016-01-07 2017-07-13 Mayo Foundation For Medical Education And Research Procédés de traitement du cancer par interféron
EP3413874A4 (fr) 2016-02-12 2020-01-22 Mayo Foundation for Medical Education and Research Traitements des cancers hématologiques
AU2017238118A1 (en) 2016-03-21 2018-10-11 Mayo Foundation For Medical Education And Research Methods for improving the therapeutic index for a chemotherapeutic drug
WO2017165440A1 (fr) 2016-03-21 2017-09-28 Mayo Foundation For Medical Education And Research Procédés de réduction de la toxicité d'un médicament chimiothérapeutique
US10618969B2 (en) 2016-04-06 2020-04-14 Mayo Foundation For Medical Education And Research Carrier-binding agent compositions and methods of making and using the same
US11160876B2 (en) 2016-09-01 2021-11-02 Mayo Foundation For Medical Education And Research Methods and compositions for targeting t-cell cancers
JP7525999B2 (ja) 2016-09-01 2024-07-31 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ キャリアー－ｐｄ－ｌ１結合剤組成物及び癌を処置する為にそれを使用する方法
WO2018048815A1 (fr) 2016-09-06 2018-03-15 Nantibodyfc, Llc Méthodes de traitement d'un cancer du sein triple-négatif à l'aide de compositions d'anticorps et de protéines porteuses
US11427637B2 (en) 2016-09-06 2022-08-30 Mayo Foundation For Medical Education And Research Methods of treating PD-L1 expressing cancer
WO2018048958A1 (fr) 2016-09-06 2018-03-15 Mayo Foundation For Medical Education And Research Compositions d'agents de liaison, de paclitaxel et d'albumine et leurs procédés d'utilisation et de production

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1546177A (en) * 1976-11-19 1979-05-16 Biokema Sa Process for the preparation of a stable injectable solution
JPS5822085B2 (ja) * 1977-07-19 1983-05-06 株式会社ミドリ十字 静注用ガンマ・グロブリン製剤
EP0303088B1 (fr) * 1987-08-10 1992-11-11 Miles Inc. IgM purifiée

Also Published As

Publication number Publication date
JPH04504253A (ja) 1992-07-30
EP0465513A1 (fr) 1992-01-15
WO1990011091A1 (fr) 1990-10-04

Similar Documents

Publication Publication Date Title
CA2049342A1 (fr) Formules pour stabiliser les anticorps igm
Sarciaux et al. Effects of buffer composition and processing conditions on aggregation of bovine IgG during freeze-drying
EP0417193B1 (fr) Preparation lyophilisee pour la stabilisation de produits a base d'anticorps
Kerwin et al. Effects of tween 80 and sucrose on acute short-term stability and long-term storage at− 20 C of a recombinant hemoglobin
AU695084B2 (en) Formulations for factor IX
US4496537A (en) Biologically stable alpha-interferon formulations
US9463241B2 (en) Method for stabilising an immunoglobulin G composition in liquid form
US20220257763A1 (en) Room temperature stable lyophilized protein
US20100056765A1 (en) Formulations That Inhibit Protein Aggregation
BR112012012080B1 (pt) Formulações de histidina-trealose do anticorpo t1h
EP0417191A1 (fr) Formule de reactifs contenant des anticorps.
JPS6191131A (ja) 医薬品の吸着防止方法および組成物
US8372798B2 (en) High-concentration protein formulations and method of manufacture
KR20040018458A (ko) Ｃｅｔｕｘｉｍａｂ 및 폴리옥시에틸렌 소르비탄 지방산에스테르를 포함하는 액형 제제
AU676833B2 (en) Pharmaceutical compositions containing IL-6
JPH11502205A (ja) ｈＣＧ液体製剤
KR900004799B1 (ko) 안정한 감마 인터페론 제제 및 이의 제조방법
KR20200143449A (ko) 메글루민 염을 사용하여 단백질을 포함하는 제형을 안정화시키는 방법
WO2021141789A1 (fr) Formulations stables de peptides anticancéreux
CA2466641A1 (fr) Compositions lyophilisees d'anticorps monoclonaux
JPH0137118B2 (fr)
RU2136313C1 (ru) Стабилизирующий состав для получения референс-сывороток, содержащих igm-антитела
JPS6399022A (ja) 静脈内投与に適したガンマ・グロプリン
AU2002337895A1 (en) Lyophilized monoclonal antibody compositions

Legal Events

Date Code Title Description
FZDE Dead